Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 72 out of 100. Risk factors

Topic: Risk, prevention and care in population studies

Objective Diabetes is associated with cognitive decline and dementia. However, the relationship between the degree of hyperglycemia and cognitive status remains unclear. This was explored using baseline cognitive measures collected in the ongoing Memory in Diabetes (MIND) substudy of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Research design and methods The relationship of A1C and fasting plasma glucose (FPG) levels to performance on four cognitive tests was assessed, adjusting for age and other determinants of cognitive status. The tests were the Digit Symbol Substitution Test (DSST), Mini Mental Status Examination (MMSE), Rey Auditory Verbal Learning Test, and Stroop Test. Results A statistically significant age-adjusted association was observed between the A1C level and the score on all four cognitive tests. Specifically, a 1% higher A1C value was associated with a significant 1.75-point lower DSST score (95% CI -1.22 to -2.28; P Conclusions Higher A1C levels are associated with lower cognitive function in individuals with diabetes. The effect of glucose lowering on cognitive function will be determined by the ongoing ACCORD-MIND trial.

Key findings

Why it matters

In people with diabetes, higher A1C levels were linked to lower scores on all four cognitive tests, suggesting worse blood sugar control goes with worse thinking. Whether lowering glucose actually improves cognitive function was not answered here and is being tested in the ongoing trial.

Study details

How this study scored 72/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 11 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 1 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 2 of 4; Senior author's track record left out, no data; Institution's track record 3 of 3; Multi-centre collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 69 of the 96 points it could be judged on, which is 72 of 100. Total 72 of 100.69 of the 96 points we could judge = 72 of 100

Published in a leading specialty journal, and it is a randomised controlled trial. Scored zero for sample size and effect reported because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 69 of the 96 points we could judge it on, which is 72 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Diabetes care)
Journal's citation record 4 / 4 Diabetes Care: journal h-index 509 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomised controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2009 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (pubmed indexes it as a clinical or observational study)
Randomised / blinded 1 / 2 Randomised (as stated in the record)
Times cited 6 / 7 Cited 452 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 23.8 citations a year over 19 year(s) since 2009
Impact for its field and year 4 / 6 Cited 20.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 11 other studies in this library
Still being cited 2 / 4 Cited 44 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 3 / 3 University of Washington: institution h-index 3,540 (OpenAlex)
Multi-centre collaboration 3 / 3 OpenAlex lists 13 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 19171735)
Free to read 2 / 2 Free to read
Points 69 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 69 of the 96 points we could judge it on is 72 out of 100.
Total 72 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Cukierman-Yaffe, T., Gerstein, H. C., Williamson, J. D., Lazar, R. M., Lovato, L., Miller, M. E., et al. (2009). Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes care. https://doi.org/10.2337/dc08-1153

Vancouver

Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes care. 2009. doi:10.2337/dc08-1153. PMID: 19171735.

BibTeX

@article{cukiermanyaffe2009-19171735,
  author  = {Cukierman-Yaffe, T. and Gerstein, H. C. and Williamson, J. D. and Lazar, R. M. and Lovato, L. and Miller, M. E. and Coker, L. H. and Murray, A. and others},
  title   = {{Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial}},
  journal = {Diabetes care},
  year    = {2009},
  doi     = {10.2337/dc08-1153},
  pmid    = {19171735},
  url     = {https://doi.org/10.2337/dc08-1153}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Risk factors

Similar studies

More on Risk factors

See all studies in Risk factors →